FLT3 and acute myeloid leukemia: Moreover, an Israeli group retrospectively analyzed 25 patients from six academic centers who received gilteritinib for FLT3-mutated R/R AML; most of them (80%) were treated with prior intensive chemotherapy and almost half (40%) with TKI therapy.